A detailed history of Mackenzie Financial Corp transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Mackenzie Financial Corp holds 29,127 shares of BCRX stock, worth $226,608. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,127
Previous 27,913 4.35%
Holding current value
$226,608
Previous $172,000 28.49%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$6.41 - $8.69 $7,781 - $10,549
1,214 Added 4.35%
29,127 $221,000
Q2 2024

Aug 14, 2024

SELL
$4.13 - $6.79 $17,940 - $29,495
-4,344 Reduced 13.47%
27,913 $172,000
Q1 2024

May 10, 2024

BUY
$4.89 - $7.65 $43,120 - $67,457
8,818 Added 37.62%
32,257 $163,000
Q4 2023

Jan 30, 2024

BUY
$4.98 - $6.77 $49,929 - $67,876
10,026 Added 74.75%
23,439 $140,000
Q3 2023

Oct 25, 2023

SELL
$6.71 - $7.92 $259,468 - $306,258
-38,669 Reduced 74.25%
13,413 $94,000
Q2 2023

Aug 03, 2023

SELL
$6.96 - $8.81 $47,314 - $59,890
-6,798 Reduced 11.55%
52,082 $366,000
Q1 2023

Apr 24, 2023

BUY
$7.94 - $11.84 $297,908 - $444,236
37,520 Added 175.66%
58,880 $491,000
Q4 2022

Feb 14, 2023

SELL
$10.5 - $14.2 $327,883 - $443,423
-31,227 Reduced 59.38%
21,360 $245,000
Q3 2022

Oct 07, 2022

BUY
$10.79 - $14.81 $312,165 - $428,468
28,931 Added 122.3%
52,587 $663,000
Q2 2022

Aug 10, 2022

BUY
$7.89 - $17.88 $46,156 - $104,598
5,850 Added 32.85%
23,656 $250,000
Q1 2022

May 13, 2022

BUY
$11.56 - $19.76 $205,837 - $351,846
17,806 New
17,806 $290,000
Q4 2021

Feb 14, 2022

SELL
$11.18 - $15.46 $116,529 - $161,139
-10,423 Closed
0 $0
Q3 2021

Nov 08, 2021

BUY
$14.21 - $17.65 $148,110 - $183,965
10,423 New
10,423 $150,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.45B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Mackenzie Financial Corp Portfolio

Follow Mackenzie Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.